Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib PK in Hepatic Impairment
NCT03983161Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fedratinib in myelofibrosis (MF) (4 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t up to 8 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity up to 8 days and 5 more. Started Sep 2019; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03983161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983161.